UBS AM’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q4
Sell
-142,131
Closed -$497K 2689
2024
Q3
$497K Sell
142,131
-46,329
-25% -$162K ﹤0.01% 2648
2024
Q2
$618K Buy
+188,460
New +$618K ﹤0.01% 2568
2023
Q4
Sell
-35,408
Closed -$75.1K 2564
2023
Q3
$75.1K Hold
35,408
﹤0.01% 2573
2023
Q2
$202K Hold
35,408
﹤0.01% 2568
2023
Q1
$202K Sell
35,408
-42,743
-55% -$244K ﹤0.01% 2568
2022
Q4
$789K Sell
78,151
-332,742
-81% -$3.36M ﹤0.01% 1970
2022
Q3
$9.21M Sell
410,893
-103,204
-20% -$2.31M 0.01% 988
2022
Q2
$12.7M Buy
514,097
+70,047
+16% +$1.74M 0.01% 872
2022
Q1
$17.2M Buy
444,050
+16,707
+4% +$648K 0.01% 880
2021
Q4
$25M Buy
427,343
+67,934
+19% +$3.97M 0.01% 845
2021
Q3
$21.3M Buy
359,409
+15,842
+5% +$939K 0.01% 846
2021
Q2
$29.8M Buy
343,567
+43,974
+15% +$3.82M 0.01% 781
2021
Q1
$24.7M Sell
299,593
-110,832
-27% -$9.14M 0.01% 808
2020
Q4
$37.3M Sell
410,425
-157,111
-28% -$14.3M 0.02% 682
2020
Q3
$22.7M Buy
567,536
+10,462
+2% +$418K 0.01% 732
2020
Q2
$19.1M Buy
557,074
+190,517
+52% +$6.54M 0.01% 754
2020
Q1
$8.14M Sell
366,557
-184,939
-34% -$4.11M 0.01% 913
2019
Q4
$10.8M Buy
551,496
+220
+0% +$4.31K 0.01% 918
2019
Q3
$8.56M Buy
551,276
+12,345
+2% +$192K 0.01% 1007
2019
Q2
$10.9M Buy
538,931
+7,230
+1% +$147K 0.01% 928
2019
Q1
$9.34M Buy
531,701
+18,197
+4% +$320K 0.01% 951
2018
Q4
$6.59M Buy
513,504
+447,726
+681% +$5.74M 0.01% 988
2018
Q3
$1.07M Buy
+65,778
New +$1.07M ﹤0.01% 1784